Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
27
TNYA Quote, Financials, Valuation and Earnings
Last price:
$0.70
Seasonality move
:
18.17%
Day range:
$0.66 - $0.70
52-week range:
$0.36 - $2.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.25x
Volume:
1.5M
Avg. volume:
5M
1-year change:
22.74%
Market cap:
$153.8M
Revenue:
--
EPS (TTM):
-$0.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNYA
Tenaya Therapeutics, Inc.
|
$2.5M | -$0.11 | -- | -59.1% | $9.00 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.1B | $1.53 | 88.89% | -58.59% | $449.32 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$754.8M | $1.00 | 3.04% | 4.71% | $88.87 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.18 | 95.36% | -52.54% | $7.87 |
|
SVRA
Savara, Inc.
|
-- | -$0.14 | -- | -12.28% | $10.81 |
|
VCEL
Vericel Corp.
|
$73M | $0.02 | 15.41% | -32.56% | $55.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNYA
Tenaya Therapeutics, Inc.
|
$0.69 | $9.00 | $153.8M | -- | $0.00 | 0% | -- |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$318.85 | $449.32 | $41B | 141.27x | $0.00 | 0% | 11.46x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$55.50 | $88.87 | $10.3B | 31.15x | $0.00 | 0% | 3.33x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.32 | $7.87 | $21.7M | -- | $0.00 | 0% | 5.44x |
|
SVRA
Savara, Inc.
|
$5.56 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
|
VCEL
Vericel Corp.
|
$34.14 | $55.43 | $1.8B | 116.03x | $0.00 | 0% | 6.60x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNYA
Tenaya Therapeutics, Inc.
|
8.08% | 2.648 | 7.02% | 6.51x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.662 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.343 | 5.63% | 3.25x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 1.671 | -- | 7.49x |
|
SVRA
Savara, Inc.
|
12.84% | -1.345 | 2.43% | 11.56x |
|
VCEL
Vericel Corp.
|
21.7% | 1.170 | 5.39% | 4.52x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNYA
Tenaya Therapeutics, Inc.
|
-$1.8M | -$20.8M | -78.2% | -87.41% | -- | -$14M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$1.9M | -77.25% | -77.25% | -170.75% | -$1.9M |
|
SVRA
Savara, Inc.
|
-$40K | -$33.4M | -67.27% | -80.59% | -- | -$25.1M |
|
VCEL
Vericel Corp.
|
$73.1M | $22.4M | 3.99% | 5.26% | 24.12% | $12.8M |
Tenaya Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns TNYA or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of 16.99%. Tenaya Therapeutics, Inc.'s return on equity of -87.41% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $134.1M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About TNYA or ALNY?
Tenaya Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 1195.71%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Tenaya Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Tenaya Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is TNYA or ALNY More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.
-
Which is a Better Dividend Stock TNYA or ALNY?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or ALNY?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Tenaya Therapeutics, Inc.'s net income of -$20.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.2M ALNYAlnylam Pharmaceuticals, Inc.11.46x 141.27x $1.1B $186.4M
-
Which has Higher Returns TNYA or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of -5.2%. Tenaya Therapeutics, Inc.'s return on equity of -87.41% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $134.1M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About TNYA or BMRN?
Tenaya Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 1195.71%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 60.13%. Given that Tenaya Therapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Tenaya Therapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is TNYA or BMRN More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.293, suggesting its less volatile than the S&P 500 by 70.697%.
-
Which is a Better Dividend Stock TNYA or BMRN?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or BMRN?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Tenaya Therapeutics, Inc.'s net income of -$20.2M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 31.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus 3.33x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.2M BMRNBioMarin Pharmaceutical, Inc.3.33x 31.15x $895M -$46.6M
-
Which has Higher Returns TNYA or MRKR?
Marker Therapeutics, Inc. has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of -154.36%. Tenaya Therapeutics, Inc.'s return on equity of -87.41% beat Marker Therapeutics, Inc.'s return on equity of -77.25%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $134.1M MRKRMarker Therapeutics, Inc.-- -$0.10 $16.8M -
What do Analysts Say About TNYA or MRKR?
Tenaya Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 1195.71%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 495.96%. Given that Tenaya Therapeutics, Inc. has higher upside potential than Marker Therapeutics, Inc., analysts believe Tenaya Therapeutics, Inc. is more attractive than Marker Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is TNYA or MRKR More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.471, suggesting its more volatile than the S&P 500 by 47.131%.
-
Which is a Better Dividend Stock TNYA or MRKR?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or MRKR?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than Marker Therapeutics, Inc. quarterly revenues of $1.1M. Tenaya Therapeutics, Inc.'s net income of -$20.2M is lower than Marker Therapeutics, Inc.'s net income of -$1.7M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus 5.44x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.2M MRKRMarker Therapeutics, Inc.5.44x -- $1.1M -$1.7M
-
Which has Higher Returns TNYA or SVRA?
Savara, Inc. has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of --. Tenaya Therapeutics, Inc.'s return on equity of -87.41% beat Savara, Inc.'s return on equity of -80.59%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $134.1M SVRASavara, Inc.-- -$0.13 $233M -
What do Analysts Say About TNYA or SVRA?
Tenaya Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 1195.71%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that Tenaya Therapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Tenaya Therapeutics, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 SVRASavara, Inc.6 0 0 -
Is TNYA or SVRA More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.
-
Which is a Better Dividend Stock TNYA or SVRA?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or SVRA?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Tenaya Therapeutics, Inc.'s net income of -$20.2M is higher than Savara, Inc.'s net income of -$32.2M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.2M SVRASavara, Inc.-- -- -- -$32.2M
-
Which has Higher Returns TNYA or VCEL?
Vericel Corp. has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of 25.02%. Tenaya Therapeutics, Inc.'s return on equity of -87.41% beat Vericel Corp.'s return on equity of 5.26%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $134.1M VCELVericel Corp.78.7% $0.45 $452.9M -
What do Analysts Say About TNYA or VCEL?
Tenaya Therapeutics, Inc. has a consensus price target of $9.00, signalling upside risk potential of 1195.71%. On the other hand Vericel Corp. has an analysts' consensus of $55.43 which suggests that it could grow by 62.36%. Given that Tenaya Therapeutics, Inc. has higher upside potential than Vericel Corp., analysts believe Tenaya Therapeutics, Inc. is more attractive than Vericel Corp..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 VCELVericel Corp.7 1 0 -
Is TNYA or VCEL More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vericel Corp. has a beta of 1.204, suggesting its more volatile than the S&P 500 by 20.404%.
-
Which is a Better Dividend Stock TNYA or VCEL?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vericel Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. Vericel Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or VCEL?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than Vericel Corp. quarterly revenues of $92.9M. Tenaya Therapeutics, Inc.'s net income of -$20.2M is lower than Vericel Corp.'s net income of $23.2M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while Vericel Corp.'s PE ratio is 116.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus 6.60x for Vericel Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.2M VCELVericel Corp.6.60x 116.03x $92.9M $23.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
